The effects of octreotide on regional motor function in the human gut are unclear. In a randomised, blinded study the effects of octreotide (50 ,ug, subcutaneously, three times daily) and placebo on gastric, small bowel, and colonic transit, and colonic motility and tone were assessed in 12 healthy volunteers whose colon had been cleansed. Octreotide accelerated initial gastric emptying (p=0.05), inhibited small bowel transit (p<0-01), and reduced ileocolonic bolus transfers (p<0.05). Colonic transit was unaltered by octreotide; the postprandial colonic tonic response was inhibited (p<0.05 v placebo), whereas colonic phasic pressure activity was increased by octreotide (p<0.05 v placebo). These data support the use of octreotide in diarrhoeal states but not in diseases that cause small bowel stasis and bacterial overgrowth. Simultaneous measurements of colonic transit, tone, and phasic contractility are valid in studying the effects of pharmacological changes and may be applicable to the study ofthe human colon in health and disease. (Gut 1995; 36: 743-748) 
While its application in these diarrhoeal disorders has received much attention, somatostatin is known to induce reproducibly a propagated activity front, similar to a migrating motor complex, in the small intestine.5-10
Thus, Soudah et al proposed its use in intestinal scleroderma,1l in which there is evidence of stasis and bacterial overgrowth. In view of these diverse indications proposed from clinical studies, ranging from severe stasis with bacterial overgrowth to severe diarrhoeas of diverse aetiologies, we undertook a study to examine in detail the regional effects of octreotide on motor function in the human gastrointestinal tract. In a previous study, we reported the effects of 50 ,ug subcutaneous octreotide on gastroduodenojejunal motility in health and disease.12 In this study, we wished to assess specifically colonic motor function in greater detail in view of the recent observation that carcinoid patients show significant changes in colon function,13 and although octreotide is frequently used in the treatment for this form of diarrhoea, its mechanism of action in these patients is unclear.
To test the hypothesis that octreotide inhibits motor function throughout the gut, and specifically colonic contractility, we evaluated its effects on gastric emptying, small bowel transit, ileocolonic transfer of solid residue, regional colonic transit, and postprandial tonic and phasic pressure activity in the colon of healthy subjects. Figure 4 : Plots of ileocolonic transit in each healthy subject in the placebo and octreotide groups. They axis indicates the percentage of isotope in the colon. Examples of bolus transfers are indicated by the arrows. Note that only one subject receiving octreotide showed a rate offlow s'10% in 15 minute periods (=boluses), whereas the placebo group showed five bolus transfers.
Results

GASTROINTESTINAL TRANSIT
Octreotide resulted in a faster initial emptying from the stomach (Table I) as shown by the lag time (p=009) and by estimates of f, the initial shape of the gastric emptying curve (p=0.048). Figure 2 shows gastric emptying plots derived from the median data for the two groups. Note the difference in the shape of the initial part of the gastric emptying curve; in contrast, the remainder of the curves look similar. Thus, the post-lag fractional gastric emptying rate and K were not significantly different in the two groups (Table I) .
Octreotide prolonged small bowel transit time (Fig 3) . There was also a reduction in the number of bolus transfers (Fig 4) across the ileocolonic junction in subjects treated with octreotide (five bolus transfers in the placebo group, while only one of the octreotide treated subjects had a bolus transfer; p<0 05 by Pearson's x2 analysis).
Ascending colon emptying rate, as well as the geometric centre (weighted average of counts in the colon) at two, eight, and 24 hours (estimates of total colonic transit) were similar in the two treatment groups (Table II) . Figure 5 shows the profiles of ascending colon transit corrected for the time of onset of colonic transit, identified by appearance of 100% of the "'In counts in the ascending colon. Two subjects given placebo seemed to have very rapid emptying of the isotope from the ascending colon; however, the remainder of the subjects had very similar profiles of ascending colon emptying characterised by linear phases and plateaux. The geometric centres at two, eight, and 24 hours were similar in the two groups, suggesting no overall effect of octreotide on transit through the prepared colon.
COLONIC MOTOR FUNCTION
Representative examples of tracings of colonic motility are shown in Figure 6 (A) (placebo) and (B) (octreotide).
Colonic tonic motility The fasting baseline barostat volumes in the two groups were not significantly different, and after the meal both groups showed a gastrocolonic response which was significantly increased in the placebo group (p<0 05) and was less marked, although still showing a trend toward significance (p=0.09) in the octreotide group (Fig 7) . The magnitude of the tonic response to the meal is best summarised by the fractional decrease in the balloon volume after the meal, and was significantly lower in the octreotide group 13 (5)% compared with the placebo group (28 (4)O/O) (p<0.05).
Colonic motility measured by manometry
The fasting colonic phasic pressure activity measured by manometry was similar in the octreotide and placebo groups. Postprandially, both groups showed a significant increase in the motility index (Fig 8) . However, the increment in phasic pressure activity in the octreotide group showed a trend to being greater than in the placebo group (p=0.09). Hence, any effect of octreotide on gastric motility to account for accelerated emptying would have to be explained on the basis of a change in an alternative motor function, such as pyloric resistance, fundic tone, or a reduction in the intestinal resistance to flow by induction of a migrating motor like complex. 12 Shortening of the lag phase is typically seen after vagotomy,27 presumably as a result of the abolition of the stomach's accommodation and inhibition of fundic tone,28 or after stimulation of highly propulsive gastric contractions by erythromycin. 29 Further studies of these motor functions will be necessary to demonstrate conclusively the mechanism whereby octreotide reduces the lag phase for solid emptying.
The similarity in the second phase of gastric emptying in the two groups may suggest that since the gastric volume load was likely smaller with octreotide, the latter may actually have slowed gastric emptying during this period.
The precise or relative contributions of volume load and emptying rate cannot be resolved by our methodology, but alternative approaches, such as magnetic resonance imaging, may be more useful. 30 The overall inhibition in the small bowel transit of solid residue measured accurately by the scintigraphic method clarifies the observations of previous studies evaluating orocaecal transit time which was appreciably delayed by octreotide in both health31 32 The pattern of delayed overall small bowel transit in the octreotide treated patients is associated with a reduction in the number of bolus transfers'4 across the ileocaecal junction.
In the one patient receiving octreotide who showed a bolus transfer, its magnitude (15%) was identical to the mean magnitude of the transfers in the placebo group (14%). Thus, although the pattern of motor mechanisms that result in bolus transfers across the ileocaecal junction is unclear,38 octreotide seems to inhibit this propulsive event in most individuals and this may contribute further to the overall retardation of small bowel transit. The presumably reduced pancreaticobiliary and intestinal secretion in the presence of octreotide may result in a lower ileal volume load and, hence, a lower contractile response by the distal ileum with the attendant reduction in the size of bolus transfers.
We were unable to show any change in overall colonic transit or in the emptying rate of the ascending region of the prepared colon. We were impressed by the rapidity with which the ascending colon and the remainder of the colon emptied in comparison with transit profiles in our previous studies15 17 Note the similarfasting value in the two groups and the greater increment postprandially in the octreotide group. normal absorptive functions. Future studies will need to explore the hypothesis that decreasing colonic tone retards overall colonic transit. The concomitant increase in colonic phasic pressure activity induced by octreotide confirms previous data in the rectum,4 and may have counteracted the potential effect on transit of reducing colonic tone. Thus, overall colonic transit was unaltered by octreotide, suggesting that the major beneficial effect in diarrhoeal disorders may be due to the retardation of small bowel transit and inhibition of small bowel secretion. 26 In summary, our study has characterised in detail the regional motor effects of octreotide in the healthy gastrointestinal tract. Data from these studies support the use of octreotide in the treatment of diarrhoea predominant illnesses. The current studies do not provide a rationale for using octreotide to treat small bowel stasis syndromes. Approaches using specific antagonists will be necessary to understand the mechanisms whereby octreotide alters motor function in the whole animal. From a methodological standpoint, our studies have proved that it is feasible to study the colon's motor function using simultaneous measurements of transit, tone, and phasic contractility. This approach seems to be advantageous as it provides a means of assessing simultaneously the functional significance of contractile activity, and may allow a clearer understanding of the processes that result in colonic propulsion in health, pharmacological perturbations, and disease. 
